Leucopenia after gold and sulphasalazine treatment Sir: I read the interesting report by Bliddal and colleagues of three patients who developed leucopenia after both gold and sulphasalazine treatment.' HLA-DR3 as a marker for toxic reactions after treatment with gold or Dpenicillamine could not be shown. Patient 1, however, was apparently a carrier of HLA-B27. It is well known that female patients with rheumatoid arthritis, who are HLA-B27 positive, have a significantly higher risk for drug induced agranulocytosis, not only after treatment with levamisole2 3 but also with other antirheumatic drugs.4 Thus under these conditions the possibility should be considered that in this patient, in the absence of HLA-D3, HLA-B27 may be the risk indicator for her relapsing leucopenia. Positive antinuclear antibodies were found in 13/24 (54%) patients with dermatomyositis without malignancy, but they were found in only 2/12 (17%) of those with malignancy (p<0 03). The low incidence of antinuclear antibodies in dermatomyositis with malignancy suggests the presence of a different serological background from that in the dermatomyositis without malignancy. This conclusion supports the view that a distinct subset of dermatomyositis exists-dermatomyositis with malignancy. MASAHIKO we wish to report our findings on the effect of xanthine oxidase inhibition in models of joint
